Navigation Links
nContact Announces Initiation of Clinical Trials for the Treatment of Atrial Fibrillation in Open-Chest Procedures
Date:11/16/2009

MORRISVILLE, N.C., Nov. 16 /PRNewswire/ -- nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for non-invasive treatment for heart conditions, today announced the initiation of a clinical trial designed to evaluate the safety and efficacy of its Numeris® - AF Tethered Coagulation System with VisiTrax® device in an open-chest concomitant procedure for the treatment of longstanding persistent atrial fibrillation (AF). This multi-center, non-randomized, prospective clinical trial will enroll up to 107 participants at 15 study sites across the United States.

"We developed our coagulation system based on the integration of suction, perfusion, and energy to create non-conductive, bi-atrial lesions. What is unique about this study is that we are creating a comprehensive lesion pattern on a beating heart to interrupt atrial fibrillation circuits located across both atria," said John P. Funkhouser, President and CEO of nContact. "Our hope is that this study will lead to participants being free from AF and completely off class I and class III antiarrhythmic drugs (AADs)* following their treatment."

The clinical trial procedure involves creating a bi-atrial lesion pattern on a beating heart to block electrical signals that cause AF. The lesions are created using nContact's tethered device on the upper chambers of the heart, the left and right atria, where the AF occurs. Once the lesions have been created, a cardiothoracic surgeon will be able to confirm intra-operatively through pacing whether the lesions are non-conductive and the pulmonary veins are isolated.

"The nContact technology enables me to create a comprehensive biatrial lesion pattern on a beating heart. We look forward to investigating the ability to treat atrial fibrillation in patients undergoing open heart surgery with the hope of establishing the lesion pattern with superior results," commented Dr. Edward Garrett, Jr., Principal Investigator from Baptist Memorial Hospital Heart Institute, Memphis.

For more information about the Numeris-AF Tethered Coagulation with VisiTrax trial, please visit www.clinicaltrials.gov (study number NCT00950092).

*The decision to stop the use of AADs will be decided by each participant's physician evaluation of the participant's medical status.

About nContact Surgical, Inc .

nContact is a medical device company founded in 2005 with the company mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF).

To date, The Numeris® Coagulation System with VisiTrax® is indicated for the coagulation of cardiac tissue (resulting in lesion creation) in the United States. nContact has initiated clinical studies for the treatment of AF in both open and closed chest procedures. The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the specific indication for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter.

    nContact, Inc.
    1001 Aviation Parkway, Ste 400
    Morrisville, NC  27560
    T (919) 466-9810
    F (919) 466-9811

    Media Contacts
    Angela Moser
    nContact Surgical, Inc.
    amoser@ncontactsurgical.com

    Scott Lerman
    The Ruth Group
    T (646) 536-7013
    slerman@theruthgroup.com

SOURCE nContact Surgical, Inc.


'/>"/>
SOURCE nContact Surgical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medicine Announces Strong Third Quarter 2009 Results
2. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
3. Chindex International Announces Participation in Brean Murray, Carret & Co. 2009 China Growth Conference
4. LifeCare Holdings, Inc. Announces Third Quarter Results
5. Telik Announces Third Quarter 2009 Financial Results
6. Quantros Announces Partnership With Hospital Accreditation Agency DNV
7. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
8. Dynatronics Announces Positive Financial Results for Quarter
9. Niusule Announces Key Additions to Management Team
10. Warner Chilcott Announces Secondary Equity Offering
11. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
(Date:2/23/2017)... 23, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ... oncology and dermatology biopharmaceutical company, today announced that it ... Rodrigues as special advisers to the Company,s Board ... the board on financial and corporate strategy. ... commitment of up to $2.5 million from Eric ...
(Date:2/23/2017)... Feb. 22, 2017 Medical Imaging ... imaging is performed to reveal the internal structures hidden ... the medical condition. It plays a vital role not ... as it is taken into consideration during the follow-up ... X-rays, SPECT/PET, ultrasound, CT, and MRI. For the diagnosis ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated this ... Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek ... winner is the Center for American Progress (CAP), for its report, Lessons From State ...
(Date:2/23/2017)... Hollywood, CA (PRWEB) , ... February 23, 2017 , ... ... pleased to announce that they are sponsoring a raffle. Throughout the month of February, ... Winners will receive a gift card for a dinner for two at the Cheesecake ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
(Date:2/23/2017)... ... , ... Thomas Vas-Don suffered from severe injury due to an ... to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” (published ... of massage, anatomy , trigger points and referral pain patterns . , ...
Breaking Medicine News(10 mins):